• Publications
  • Influence
Formulating retirement targets and the impact of time horizon on asset allocation
This paper looks at standard retirement targets such as “70@65,” meaning 70% income replacement at age 65, and reconsiders them in a probabilistic setting. The paper uses a chance constrainedExpand
  • 31
  • 7
  • PDF
The role of cell signalling in the crosstalk between autophagy and apoptosis.
Not surprisingly, the death of a cell is a complex and well controlled process. For several decades, apoptosis, the first genetically programmed death process to be identified has taken centre stageExpand
  • 215
  • 6
Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells
The present studies determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with clinically relevant chemotherapies to kill gastrointestinal/genitourinary cancerExpand
  • 47
  • 2
  • PDF
Syntax PAL: a system to improve the written syntax of language-impaired users.
TLDR
Syntax PAL uses the syntax of the initial part of a sentence to enhance the position in the prediction list of syntactically correct words to encourage the use of correct syntax. Expand
  • 14
  • 2
What Drives Shareholder Value ?
  • 16
  • 2
  • PDF
OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing
We have further defined mechanism(s) by which the drug OSU-03012 (OSU) kills tumor cells. OSU lethality was suppressed by knock down of PERK and enhanced by knock down of ATF6 and IRE1α. OSUExpand
  • 37
  • 1
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
The present studies examined viability and DNA damage levels in mammary carcinoma cells following PARP1 and CHK1 inhibitor drug combination exposure. PARP1 inhibitors [AZD2281 ; ABT888 ; NU1025 ;Expand
  • 45
  • 1
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells
We determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with clinically relevant chemotherapies to kill medulloblastoma cells. In medulloblastoma cells PDE5Expand
  • 39
  • 1
Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic
We determined whether the approved myelofibrosis drug ruxolitinib (Jakafi®), an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could be repurposed as an anti-cancer agent for solid tumors.Expand
  • 25
  • 1
  • PDF